检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218)

Peter C. Thuss-Patience, Anica Hoegner,Eray Goekkurt,Michael Stahl, Albrecht Kretzschmar,Thorsten Oliver Goetze,Gertraud Stocker,Peter Reichardt,Frank Kullmann,Daniel Pink, Prisca Bartels, Armin Jarosch,Axel Hinke,Lisa Paschold,Alexander Stein,Mascha Binder

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用 0|浏览18
暂无评分
关键词
esophagogastric adenocarcinoma,paclitaxel,ramucirumab,rap trial,aio-sto
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要